Mavoglurant in Fragile X Syndrome: Results of two open-label, extension trials in adults and adolescents

Randi J Hagerman, Sebastien Jacquemont, Elizabeth Berry-Kravis, Vincent Des Portes, Andrew Stanfield, Barbara Koumaras, Gerd Rosenkranz, Alessandra Murgia, Christian Wolf, George Apostol, Florian von Raison

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Fragile X syndrome (FXS) is the most common monogenic cause of inherited intellectual and developmental disabilities. Mavoglurant, a selective metabotropic glutamate receptor subtype-5 antagonist, has shown positive neuronal and behavioral effects in preclinical studies, but failed to demonstrate any behavioral benefits in two 12-week, randomized, placebo-controlled, double-blind, phase IIb studies in adults and adolescents with FXS. Here we report the long-term safety (primary endpoint) and efficacy (secondary endpoint) results of the open-label extensions. Adolescent (n = 119, aged 12–19 years) and adult (n = 148, aged 18–45 years) participants received up to 100 mg bid mavoglurant for up to 34 months. Both extension studies were terminated prematurely due to lack of proven efficacy in the core studies. Mavoglurant was well tolerated with no new safety signal. Five percent of adults and 16.9 percent of adolescents discontinued treatment due to adverse events. Gradual and consistent behavioral improvements as measured by the ABC-CFX scale were observed, which were numerically superior to those seen in the placebo arm of the core studies. These two extension studies confirm the long-term safety of mavoglurant in FXS, but further investigations are required to determine whether and under which conditions the significant preclinical results obtained with mGluR5 inhibition can translate to humans.

Original languageEnglish (US)
Article number16970
JournalScientific Reports
Volume8
Issue number1
DOIs
StatePublished - Dec 1 2018

Fingerprint

Fragile X Syndrome
Safety
Metabotropic Glutamate 5 Receptor
Placebos
Developmental Disabilities
Intellectual Disability
mavoglurant
Therapeutics

ASJC Scopus subject areas

  • General

Cite this

Hagerman, R. J., Jacquemont, S., Berry-Kravis, E., Des Portes, V., Stanfield, A., Koumaras, B., ... von Raison, F. (2018). Mavoglurant in Fragile X Syndrome: Results of two open-label, extension trials in adults and adolescents. Scientific Reports, 8(1), [16970]. https://doi.org/10.1038/s41598-018-34978-4

Mavoglurant in Fragile X Syndrome : Results of two open-label, extension trials in adults and adolescents. / Hagerman, Randi J; Jacquemont, Sebastien; Berry-Kravis, Elizabeth; Des Portes, Vincent; Stanfield, Andrew; Koumaras, Barbara; Rosenkranz, Gerd; Murgia, Alessandra; Wolf, Christian; Apostol, George; von Raison, Florian.

In: Scientific Reports, Vol. 8, No. 1, 16970, 01.12.2018.

Research output: Contribution to journalArticle

Hagerman, RJ, Jacquemont, S, Berry-Kravis, E, Des Portes, V, Stanfield, A, Koumaras, B, Rosenkranz, G, Murgia, A, Wolf, C, Apostol, G & von Raison, F 2018, 'Mavoglurant in Fragile X Syndrome: Results of two open-label, extension trials in adults and adolescents', Scientific Reports, vol. 8, no. 1, 16970. https://doi.org/10.1038/s41598-018-34978-4
Hagerman, Randi J ; Jacquemont, Sebastien ; Berry-Kravis, Elizabeth ; Des Portes, Vincent ; Stanfield, Andrew ; Koumaras, Barbara ; Rosenkranz, Gerd ; Murgia, Alessandra ; Wolf, Christian ; Apostol, George ; von Raison, Florian. / Mavoglurant in Fragile X Syndrome : Results of two open-label, extension trials in adults and adolescents. In: Scientific Reports. 2018 ; Vol. 8, No. 1.
@article{74dc1a10a7824396abaccec51561251a,
title = "Mavoglurant in Fragile X Syndrome: Results of two open-label, extension trials in adults and adolescents",
abstract = "Fragile X syndrome (FXS) is the most common monogenic cause of inherited intellectual and developmental disabilities. Mavoglurant, a selective metabotropic glutamate receptor subtype-5 antagonist, has shown positive neuronal and behavioral effects in preclinical studies, but failed to demonstrate any behavioral benefits in two 12-week, randomized, placebo-controlled, double-blind, phase IIb studies in adults and adolescents with FXS. Here we report the long-term safety (primary endpoint) and efficacy (secondary endpoint) results of the open-label extensions. Adolescent (n = 119, aged 12–19 years) and adult (n = 148, aged 18–45 years) participants received up to 100 mg bid mavoglurant for up to 34 months. Both extension studies were terminated prematurely due to lack of proven efficacy in the core studies. Mavoglurant was well tolerated with no new safety signal. Five percent of adults and 16.9 percent of adolescents discontinued treatment due to adverse events. Gradual and consistent behavioral improvements as measured by the ABC-CFX scale were observed, which were numerically superior to those seen in the placebo arm of the core studies. These two extension studies confirm the long-term safety of mavoglurant in FXS, but further investigations are required to determine whether and under which conditions the significant preclinical results obtained with mGluR5 inhibition can translate to humans.",
author = "Hagerman, {Randi J} and Sebastien Jacquemont and Elizabeth Berry-Kravis and {Des Portes}, Vincent and Andrew Stanfield and Barbara Koumaras and Gerd Rosenkranz and Alessandra Murgia and Christian Wolf and George Apostol and {von Raison}, Florian",
year = "2018",
month = "12",
day = "1",
doi = "10.1038/s41598-018-34978-4",
language = "English (US)",
volume = "8",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Mavoglurant in Fragile X Syndrome

T2 - Results of two open-label, extension trials in adults and adolescents

AU - Hagerman, Randi J

AU - Jacquemont, Sebastien

AU - Berry-Kravis, Elizabeth

AU - Des Portes, Vincent

AU - Stanfield, Andrew

AU - Koumaras, Barbara

AU - Rosenkranz, Gerd

AU - Murgia, Alessandra

AU - Wolf, Christian

AU - Apostol, George

AU - von Raison, Florian

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Fragile X syndrome (FXS) is the most common monogenic cause of inherited intellectual and developmental disabilities. Mavoglurant, a selective metabotropic glutamate receptor subtype-5 antagonist, has shown positive neuronal and behavioral effects in preclinical studies, but failed to demonstrate any behavioral benefits in two 12-week, randomized, placebo-controlled, double-blind, phase IIb studies in adults and adolescents with FXS. Here we report the long-term safety (primary endpoint) and efficacy (secondary endpoint) results of the open-label extensions. Adolescent (n = 119, aged 12–19 years) and adult (n = 148, aged 18–45 years) participants received up to 100 mg bid mavoglurant for up to 34 months. Both extension studies were terminated prematurely due to lack of proven efficacy in the core studies. Mavoglurant was well tolerated with no new safety signal. Five percent of adults and 16.9 percent of adolescents discontinued treatment due to adverse events. Gradual and consistent behavioral improvements as measured by the ABC-CFX scale were observed, which were numerically superior to those seen in the placebo arm of the core studies. These two extension studies confirm the long-term safety of mavoglurant in FXS, but further investigations are required to determine whether and under which conditions the significant preclinical results obtained with mGluR5 inhibition can translate to humans.

AB - Fragile X syndrome (FXS) is the most common monogenic cause of inherited intellectual and developmental disabilities. Mavoglurant, a selective metabotropic glutamate receptor subtype-5 antagonist, has shown positive neuronal and behavioral effects in preclinical studies, but failed to demonstrate any behavioral benefits in two 12-week, randomized, placebo-controlled, double-blind, phase IIb studies in adults and adolescents with FXS. Here we report the long-term safety (primary endpoint) and efficacy (secondary endpoint) results of the open-label extensions. Adolescent (n = 119, aged 12–19 years) and adult (n = 148, aged 18–45 years) participants received up to 100 mg bid mavoglurant for up to 34 months. Both extension studies were terminated prematurely due to lack of proven efficacy in the core studies. Mavoglurant was well tolerated with no new safety signal. Five percent of adults and 16.9 percent of adolescents discontinued treatment due to adverse events. Gradual and consistent behavioral improvements as measured by the ABC-CFX scale were observed, which were numerically superior to those seen in the placebo arm of the core studies. These two extension studies confirm the long-term safety of mavoglurant in FXS, but further investigations are required to determine whether and under which conditions the significant preclinical results obtained with mGluR5 inhibition can translate to humans.

UR - http://www.scopus.com/inward/record.url?scp=85056701208&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056701208&partnerID=8YFLogxK

U2 - 10.1038/s41598-018-34978-4

DO - 10.1038/s41598-018-34978-4

M3 - Article

C2 - 30451888

AN - SCOPUS:85056701208

VL - 8

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

IS - 1

M1 - 16970

ER -